Supplementary Figure 3. The proportions of patients with serum HBsAg <2 log IU/mL, 2–3 log IU/mL, >3 log IU/mL as categorized by absence or presence of subsequent clinical relapse were respectively 42.4% (n=42) vs. 11.5% (n=12), 36.4% (n=36) vs. 54.8% (n=57), and 21.2% (n=21) vs. 33.7% (n=35) at treatment cessation (A), 44.3% (n=35) vs. 11.4% (n=4), 34.2% (n=27) vs. 51.4% (n=18), and 21.5% (n=17) vs. 37.2% (n=13) at one year (B), and 47.4% (n=27) vs. 14.3% (n=2), 36.8% (n=21) vs. 57.1% (n=8), and 15.8% (n=9) vs. 28.6% (n=4), respectively at the two years (C). HBsAg, hepatitis B surface antigen; CR, clinical relapse.